HER2 inhibition in these breast cancers can inhibit downstream PI3K-AKT signalling and induce antibody-dependent cell-mediated cytotoxicity, leading to up-regulation of programmed cell death protein 1 expression.48 This evidence concerns the gene ERBB2 and breast carcinoma.